We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 61-80 of 10,000 results
  1. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

    Background and Objective

    Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The...

    Anne-Kristina Mercier, Mikael Sunnåker, ... Jan Oscarsson in Clinical Pharmacokinetics
    Article Open access 06 October 2023
  2. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

    Background

    Dermatomyositis is an idiopathic inflammatory myopathy characterised by rashes and progressive muscle weakness. The recent ProDERM...

    Rohit Aggarwal, Joachim Schessl, ... Todd Levine in Arthritis Research & Therapy
    Article Open access 17 January 2024
  3. A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers

    Introduction

    Transforming growth factor beta (TGFβ) cytokines (TGFβ1, TGFβ2, and TGFβ3) play critical roles in tissue fibrosis. However, treatment...

    Lyrialle W. Han, Samira Jamalian, ... Sara Glickstein in Rheumatology and Therapy
    Article Open access 25 April 2024
  4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials

    This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 after oral single rising doses (SRDs) or multiple...

    Diane Wong, Friedeborg Seitz, ... Friedrich Schulze in Naunyn-Schmiedeberg's Archives of Pharmacology
    Article Open access 24 May 2024
  5. Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study

    Introduction

    Atopic dermatitis (AD) is a chronic disease that occurs mainly in children. Topical corticosteroids are the main treatment for mild to...

    Mehdi Sowlati, Silviu-Horia Morariu, ... Cristian Gainaru in Dermatology and Therapy
    Article Open access 23 September 2023
  6. Safety and Tolerability

    The most common adverse effects of tDCS are erythema (skin redness), burning, tingling, itching, headache, and discomfort on the site of stimulation....
    Mohammad Ali Salehinejad, Stevan Nikolin, ... André R. Brunoni in Transcranial Direct Current Stimulation in Neuropsychiatric Disorders
    Chapter 2021
  7. Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

    Background

    Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20–40% of immunocompromised people...

    Isabel H. Gonzalez-Bocco, Katherine Beluch, ... Sophia Koo in Pilot and Feasibility Studies
    Article Open access 16 June 2023
  8. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study

    Background

    Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive...

    Jelle R. Miedema, Catharina C. Moor, ... Rémy L. M. Mostard in Respiratory Research
    Article Open access 28 May 2022
  9. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects

    Background

    Nerve growth factor (NGF), the first-discovered member of the neurotrophin family, has long been regarded as a potential drug to combat...

    Qi Shen, Mengyu Zhang, ... Zhenlei Wang in CNS Drugs
    Article 22 February 2023
  10. Assessment of wound healing efficacy and tolerability using Cicatryl™ cream based on a suction blister model in healthy subjects

    Background

    Cicatryl™ cream, a topical medical device, is indicated for the treatment of superficial wounds and small skin injuries.

    Objectives ...
    Alexia Brocario, Stephan Maurel, ... Stephanie Favrel in European Journal of Dermatology
    Article 01 November 2022
  11. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial

    Background

    Tecarfarin (ATI-5923), a structural analog of warfarin, was designed to provide more uniform and stable anticoagulation.

    Objective ...
    Qiang Zhou, Zhiqiang Wang, ... Wei Hu in American Journal of Cardiovascular Drugs
    Article 09 January 2023
  12. OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

    Background

    OCE-205, a novel, selective vasopressin V1a receptor mixed agonist/antagonist with no V2 receptor activity, may treat the portal...

    Yu Bagger, William R. Ravis, ... Stan Bukofzer in Clinical Drug Investigation
    Article Open access 22 August 2023
  13. A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS

    Thyroid hormones are essential during developmental myelination and may play a direct role in remyelination and repair in the adult central nervous...

    Scott D. Newsome, Fan Tian, ... Peter A. Calabresi in Neurotherapeutics
    Article Open access 17 July 2023
  14. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects

    Background

    ACD856 is a positive allosteric modulator of tropomyosin receptor kinase (Trk) receptors which has shown to have pro-cognitive and...

    K. Önnestam, B. Nilsson, ... Märta Segerdahl in The Journal of Prevention of Alzheimer's Disease
    Article Open access 12 July 2023
  15. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records

    Background and Objective

    Real-world evidence studies of brivaracetam (BRV) have been restricted in scope, location, and patient numbers. The objective...

    Vicente Villanueva, Cédric Laloyaux, ... Bernhard J. Steinhoff in CNS Drugs
    Article Open access 09 September 2023
  16. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag

    Background

    Understanding patients’ perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient...

    Stacy Davis, Teresa Edwards, ... John Fastenau in Journal of Patient-Reported Outcomes
    Article Open access 18 December 2023
  17. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

    Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor...

    Vinod Metta, Huzaifa Ibrahim, ... K. Ray Chaudhuri in Journal of Neural Transmission
    Article Open access 05 October 2023
  18. An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

    Background

    The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease,...

    Katherine E. Olson, Mai M. Abdelmoaty, ... Howard E. Gendelman in Translational Neurodegeneration
    Article Open access 22 May 2023
  19. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults

    Background

    Neurodegenerative diseases are devastating conditions that most commonly affect individuals 65 years and older. Currently there are no...

    M. H. Silverman, S. Duggan, ... B. Wallner in The Journal of Prevention of Alzheimer's Disease
    Article 29 August 2022
  20. Efficacy and gastrointestinal tolerability of methotrexate in late-onset rheumatoid arthritis patients: a prospective cohort study

    Background

    The proportion of the late-onset forms of disease is growing in rheumatoid arthritis (RA) population. Concerns about comorbidities and drug...

    Esra Dilsat Bayrak, Ilknur Aktas in Egyptian Rheumatology and Rehabilitation
    Article Open access 13 February 2023
Did you find what you were looking for? Share feedback.